


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original): A compound represented by general formula (I):



a prodrug thereof, or a pharmaceutically acceptable salt thereof,

wherein

$R^1$  is a hydrogen atom or a lower alkyl group;

$R^2$  is:

- a) a lower alkyl group,
- b) a halo-lower alkyl group,
- c) a hydroxy-lower alkyl group,
- d) a cycloalkyl group,
- e) an aryl-cycloalkyl group,
- f) a heterocycloalkyl group,
- g) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

h) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

i) an aryl-alkenyl group, wherein the ring of the aryl-alkenyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

j) a lower alkyl group substituted with a group selected from a lower alkoxy group or a lower acyloxy group,

k) an aryloxy-lower alkyl group, wherein the ring of the aryloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

l) an aralkyloxy-lower alkyl group, wherein the ring of the aralkyloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

m) an arylsulfanyl-lower alkyl group, wherein the ring of the arylsulfanyl-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

n) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of  $X^6$ ,  $X^7$  and  $X^8$ , or

o) a heteroaryl-lower alkyl group, wherein the ring of the heteroaryl-lower alkyl group is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of  $X^6$ ,  $X^7$  and  $X^8$ ;

$X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are each independently:

a) a halogen atom,

- b) a lower alkyl group,
- c) a halo-lower alkyl group,
- d) a cycloalkyl group,
- e) a lower alkoxy group,
- f) a halo-lower alkoxy group,
- g) a cycloalkyloxy group,
- h) a heterocycloalkyloxy group,
- i) a lower alkoxy-lower alkoxy group,
- j) a hydroxy-lower alkyl group,
- k) a hydroxyl group,
- l) a carboxy group,
- m) a lower alkoxycarbonyl group,
- n) an aralkyloxycarbonyl group,
- o) a lower acyl group,
- p) a cyano group,
- q)  $-A^1-NR^{20}R^{21}$ ,
- r)  $-A^2-SR^{22}$ ,
- s)  $-SO_2NR^{23}R^{24}$ ,
- t) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

u) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

v) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

w) a heteroaryloxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or

x) a lower alkoxy group substituted with a group selected from an aryl group or a heteroaryl group, or

when two of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are adjacent each other, they are bonded together to form a group represented by  $-O-(CH_2)_m-O-$ ,  $-O-(CH_2)_n-$  or  $-(CH_2)_p-$ ;

$R^{20}$  and  $R^{21}$  are each independently a hydrogen atom, a lower alkyl group, a cycloalkyl group, a heterocycloalkyl group, a bridged cyclic hydrocarbon group, a heteroaryl-lower alkyl group, a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, a lower acyl group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group or a di(lower alkyl)amino-lower alkyl group, or

$R^{20}$  and  $R^{21}$ , taken together with the nitrogen atom to which they are bonded, form a cyclic amino group, wherein the cyclic amino group is unsubstituted or substituted with one or two substituents selected independently from the group consisting of:

- a) a lower alkyl group,
- b) a cycloalkyl group,
- c) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,
- d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group, or adjacent ring-carbon atoms of the aralkyl group are substituted with  $-O-(CH_2)_m-O-$ ,
- e) a heteroaryl group,
- f) a heteroaryl-lower alkyl group,
- g) a lower alkyl group substituted with a group selected from a hydroxyl group, a lower alkoxy group, a carboxy group, an aralkyloxycarbonyl group, a cyclic aminocarbonyl group or a di(lower alkyl)amino group,
- h) a hydroxyl group,
- i) an oxo group,
- j) a lower alkoxy carbonyl group,
- k) an aralkyloxycarbonyl group,
- l) a carbamoyl group,

- m) a lower acyl group,
- n) a benzoyl group,
- o) a di(lower alkyl)amino group, and
- p) a diphenylmethylene group;

$A^1$  is a bond, a  $C_{1-3}$ -alkylene group or a carbonyl group;

$A^2$  is a bond or a  $C_{1-3}$ -alkylene group;

$R^{22}$  is:

- a) a lower alkyl group,
- b) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,
- c) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group, or
- d) a di(lower alkyl)amino-lower alkyl group;

$R^{23}$  and  $R^{24}$  are each independently a hydrogen atom or a lower alkyl group, or

$R^{23}$  and  $R^{24}$ , taken together with the nitrogen atom to which they are bonded, form a cyclic amino group, wherein the cyclic amino group is unsubstituted or substituted with a group selected from a lower alkyl group or an aralkyl group;

m is 1 or 2;

n is 2 or 3;

p is 3 or 4;

$X^6$ ,  $X^7$  and  $X^8$  are each independently:

- a) a halogen atom,
- b) a lower alkyl group,
- c) a halo-lower alkyl group,
- d) a hydroxy-lower alkyl group,
- e) a cycloalkyl group,
- f) a heterocycloalkyl-lower alkyl group,
- g) a lower alkoxy group,
- h) a halo-lower alkoxy group,
- i) a lower acyl group,
- j) a carboxy group,
- k)  $-A^1-NR^{20}R^{21}$ ,
- l)  $-A^2-SR^{22}$ ,
- m)  $-SO_2NR^{23}R^{24}$ ,
- n) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,
- o) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,
- p) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower

alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

q) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group,

r) a heteroaryloxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or

s) an aralkyloxy group;

$R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are each independently:

- a) a hydrogen atom,
- b) a halogen atom,
- c) a lower alkyl group,
- d) a halo-lower alkyl group,
- e) a lower alkoxy group,
- f) a halo-lower alkoxy group,
- g) a hydroxyl group,
- h) a cyano group,

i) an aryl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

j) an aralkyloxy group, wherein the ring of the aralkyloxy group is unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group and a halo-lower alkoxy group,

k) a di(lower alkyl)amino group,

l) a lower alkylsulfanyl group, or

m) a nitro group, or

when two of  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are adjacent each other, they are bonded together to form a group represented by  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ , provided that at least one of  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  is other than a hydrogen atom;

with the proviso that the following compounds are excluded:

- (1) 1-acetylaminonaphtho[2,1-b]furan-2-carboxamide,
- (2) 1-benzoylaminonaphtho[2,1-b]furan-2-carboxamide,
- (3) 3-benzoylamino-5-chlorobenzofuran-2-carboxamide,
- (4) 5-chloro-3-[2-(3,4-diethoxyphenyl)acetylamino]-benzofuran-2-carboxamide,
- (5) 5-bromo-3-[2-(3,4-diethoxyphenyl)acetylamino]-benzofuran-2-carboxamide,
- (6) 5-chloro-3-(2-chloroacetylamino)benzofuran-2-

carboxamide, and

(7) 3-acetylamino-5-chlorobenzofuran-2-carboxamide.

2. (original): The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is a hydrogen atom.

3. (original): The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein  $R^3$  is a hydrogen atom.

4. (original): The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein

$R^2$  is:

- a) a lower alkyl group,
- b) a cycloalkyl group,
- c) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,
- d) an aralkyl group, wherein the ring of the aralkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,
- e) a lower alkoxy-lower alkyl group,
- f) an aryloxy-lower alkyl group, wherein the ring of the aryloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ ,

g) an aralkyloxy-lower alkyl group, wherein the ring of the aralkyloxy-lower alkyl group is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ , or

h) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of  $X^6$ ,  $X^7$  and  $X^8$ ; and

$X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^6$ ,  $X^7$  and  $X^8$  are as defined in claim 1.

5. (original): The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein  $R^4$ ,  $R^5$  and  $R^6$  are each independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group or a lower alkoxy group, provided that at least one of  $R^4$ ,  $R^5$  and  $R^6$  is other than a hydrogen atom.

6. (original): The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein

$R^2$  is:

- a) a cycloalkyl group,
- b) an aryl group, unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$ , or
- c) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of  $X^6$ ,  $X^7$  and  $X^8$ .

7. (original): The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein

$X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are each independently:

- a) a halogen atom,
- b) a lower alkyl group,
- c) a lower alkoxy group,
- d) a halo-lower alkoxy group,
- e) a heterocycloalkyloxy group,
- f) a hydroxyl group,
- g)  $-A^1-NR^{20}R^{21}$ ,
- h)  $-A^2-SR^{22}$ ,
- i)  $-SO_2NR^{23}R^{24}$ ,
- j) a heteroaryl group, unsubstituted or substituted with 1 to 3 substituents selected

independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and di(lower alkyl)amino-lower alkyl group, or

when two of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$  and  $X^5$  are adjacent each other, they are bonded together to form  $-OCH_2O-$ ; and

$X^6$ ,  $X^7$  and  $X^8$  are each independently:

- a) a halogen atom,
- b) a lower alkyl group,
- c) a hydroxy-lower alkyl group,

- d) a cycloalkyl group,
  - e) a heterocycloalkyl-lower alkyl group,
  - f)  $-A^1-NR^{20}R^{21}$ ,
  - g)  $-SO_2NR^{23}R^{24}$ ,
  - h) a phenyl group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group, or
  - i) a phenoxy group, unsubstituted or substituted with 1 to 3 substituents selected independently from the group consisting of a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group and a di(lower alkyl)amino-lower alkyl group;
- and

$A^1$ ,  $A^2$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  are as defined in claim 1.

8. (original): The compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

- (1) 3-cyclopropanecarbonylamino-5-fluorobenzo furan-2-carboxamide;
- (2) 5-chloro-3-cyclopropanecarbonylamino benzo furan-2-carboxamide;
- (3) 3-(3-fluorobenzoylamino)-6-methoxybenzofuran-2-carboxamide;
- (4) 3-(4-fluorobenzoylamino)-6-methoxybenzofuran-2-

carboxamide;

(5) 5-fluoro-3-(3-methylbenzoylamino)benzofuran-2-

carboxamide;

(6) 3-(benzo[1,3]dioxole-5-carbonyl)amino-6-fluoro-

benzofuran-2-carboxamide;

(7) 5-chloro-3-(furan-2-carbonyl)aminobenzofuran-2-

carboxamide;

(8) 5,7-difluoro-3-(furan-2-carbonyl)aminobenzofuran-2-

carboxamide;

(9) 5,7-difluoro-3-(5-methylfuran-2-carbonyl)amino-

benzofuran-2-carboxamide;

(10) 3-(5-ethylfuran-2-carbonyl)amino-5-fluorobenzofuran-

2-carboxamide;

(11) 3-(5-ethylfuran-2-carbonyl)amino-5,7-difluoro-

benzofuran-2-carboxamide;

(12) 6-methoxy-3-(5-phenylfuran-2-carbonyl)aminobenzofuran-

2-carboxamide;

(13) 6-fluoro-3-(6-phenoxy pyridine-3-carbonyl)amino-

benzofuran-2-carboxamide;

(14) 6-methoxy-3-(2-methoxyacetyl amino)benzofuran-2-

carboxamide;

(15) 3-[2-(4-chlorophenoxy)acetyl amino]-5-fluorobenzofuran-

2-carboxamide;

(16) 3-(2-benzyloxyacetylamino)-5-fluorobenzofuran-2-carboxamide;

(17) 6-chloro-3-cyclopropanecarbonylamino benzofuran-2-carboxamide;

(18) 3-cyclopropanecarbonylamino-5,7-difluorobenzofuran-2-carboxamide;

(19) 7-chloro-3-cyclopropanecarbonylamino-5-fluorobenzofuran-2-carboxamide;

(20) 3-cyclopropanecarbonylamino-5-fluoro-7-methoxybenzofuran-2-carboxamide;

(21) 3-cyclobutanecarbonylamino-5,7-difluorobenzofuran-2-carboxamide;

(22) 5-fluoro-7-methoxy-3-(4-methoxybenzoylamino)benzofuran-2-carboxamide;

(23) 5,7-difluoro-3-phenylacetylaminobenzofuran-2-carboxamide;

(24) 5,7-difluoro-3-[3-(4-methylpiperazine-1-carbonyl)benzoylamino]benzofuran-2-carboxamide;

(25) 6-methoxy-3-[3-(4-phenylpiperazin-1-ylmethyl)benzoylamino]benzofuran-2-carboxamide;

(26) 6-methoxy-3-[4-(1-methyl-1H-imidazol-2-ylsulfanyl-

methyl)benzoylamino]benzofuran-2-carboxamide;

(27) 3-[5-(4-benzylpiperazin-1-ylmethyl)furan-2-carbonyl]-amino-5,7-difluorobenzofuran-2-carboxamide;

(28) 3-[5-(4-benzo[1,3]dioxol-5-ylmethylpiperazin-1-ylmethyl)furan-2-carbonyl]amino-5,7-difluorobenzofuran-2-carboxamide;

(29) tert-butyl 4-[5-(2-carbamoyl-5,7-difluorobenzofuran-3-ylcarbamoyl)furan-2-ylmethyl]piperazine-1-carboxylate, and

(30) 5-fluoro-3-[5-(1-hydroxyethyl)furan-2-carbonyl]amino-benzofuran-2-carboxamide.

9. (currently amended): A pharmaceutical composition which comprises, as an active ingredient, a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof.

10. (currently amended): A therapeutic or prophylactic agent for a disease mediated by adenosine A<sub>2A</sub> receptors, which comprises, as an active ingredient, a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof.

11. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A<sub>2A</sub> receptors is a motor function disorder.

12. (original): The therapeutic or prophylactic agent according to claim 11, wherein the motor function disorder is Parkinson's disease, Huntington's disease or Wilson's disease.
13. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A<sub>2A</sub> receptors is depression or an anxiety disorder.
14. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A<sub>2A</sub> receptors is a cognitive function disorder.
15. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A<sub>2A</sub> receptors is a cerebral ischemia disorder.
16. (original): The therapeutic or prophylactic agent according to claim 10, wherein the disease mediated by adenosine A<sub>2A</sub> receptors is restless legs syndrome.
17. (currently amended): A pharmaceutical combination comprising a compound according to ~~any one of claims 1 to 8~~ claim 1 or a pharmaceutically acceptable salt thereof and at least one selected from anti-Parkinson drugs, antidepressants, drugs for cognitive function disorders and drugs for cerebral ischemia disorders other than adenosine A<sub>2A</sub> receptor antagonists.

18. (currently amended): A use of a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a disease mediated by adenosine A<sub>2A</sub> receptors.

19. (currently amended): A method for treating or preventing a disease mediated by adenosine A<sub>2A</sub> receptors, which comprises administering an effective amount of a compound according to ~~any one of claims 1 to 8~~claim 1 or a pharmaceutically acceptable salt thereof.